What is the share price of Piramal Pharma Ltd (Mumbai) (PPLPHARMA) today?
The share price of PPLPHARMA as on 18th September 2026 is ₹208.16. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Piramal Pharma Ltd (Mumbai) (PPLPHARMA) share?
The past returns of Piramal Pharma Ltd (Mumbai) (PPLPHARMA) share are- Past 1 week: -0.50%
- Past 1 month: 1.80%
- Past 3 months: 29.94%
- Past 6 months: 45.44%
- Past 1 year: 2.38%
- Past 3 years: 106.00%
- Past 5 years: 12.19%
What are the peers or stocks similar to Piramal Pharma Ltd (Mumbai) (PPLPHARMA)?
The peers or stocks similar to Piramal Pharma Ltd (Mumbai) (PPLPHARMA) include:What is the market cap of Piramal Pharma Ltd (Mumbai) (PPLPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Piramal Pharma Ltd (Mumbai) (PPLPHARMA) is ₹27581.58 Cr as of 18th September 2026.What is the 52 week high and low of Piramal Pharma Ltd (Mumbai) (PPLPHARMA) share?
The 52-week high of Piramal Pharma Ltd (Mumbai) (PPLPHARMA) is ₹231.93 and the 52-week low is ₹132.30.What is the PE and PB ratio of Piramal Pharma Ltd (Mumbai) (PPLPHARMA) stock?
The P/E (price-to-earnings) ratio of Piramal Pharma Ltd (Mumbai) (PPLPHARMA) is -84.62. The P/B (price-to-book) ratio is 3.38.Which sector does Piramal Pharma Ltd (Mumbai) (PPLPHARMA) belong to?
Piramal Pharma Ltd (Mumbai) (PPLPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Piramal Pharma Ltd (Mumbai) (PPLPHARMA) shares?
You can directly buy Piramal Pharma Ltd (Mumbai) (PPLPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Piramal Pharma Ltd (Mumbai)
PPLPHARMA Share Price
NSE₹208.161.96% (+4.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PPLPHARMA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PPLPHARMA Performance & Key Metrics
PPLPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -87.94 | 3.38 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.20 | 5.92 | 0.48% |
100%
Analysts have suggested that investors can buy this stock
from 10 analysts
Price Upside
Earnings Growth
Rev. Growth
PPLPHARMA Company Profile
Piramal Pharma Limited provides a diverse range of pharmaceutical products globally, including contract development and manufacturing services across various therapeutic areas.
SUNPHARMA
PE Ratio
38.40
38.40
1Y Return
11.45%
11.45%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
85.10
85.10
1Y Return
35.67%
35.67%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.96
22.96
1Y Return
10.70%
10.70%
Buy Reco %
55.56
55.56
CIPLA
PE Ratio
29.04
29.04
1Y Return
11.64%
11.64%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
111.64%
111.64%
Buy Reco %
58.33
58.33
PPLPHARMA Sentiment Analysis
PPLPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
PPLPHARMA Stock Summary · July 2026
Management said the year began strongly, with broad-based growth and sharper profitability, even as they kept full-year guidance unchanged for now. Revenue from operations rose 17% year over year to INR 2,270 crore and EBITDA increased 72% to INR 285 crore, lifting margin by about 400 basis points to 12.5%, with all three businesses delivering mid-to-high teen growth. CDMO demand reaccelerated as stronger execution, better US biopharma funding and rising RFP activity broadened the pipeline, while a deliberate land-and-expand approach deepened relationships with larger customers across sites and geographies. Management also highlighted continued buildout of the ADC and sterile fill-finish platform, including the new Riverview payload-linker facility and Lexington’s on-track expansion, alongside a low-capex capacity add-on that is already attracting interest. Consumer healthcare posted mid-teen growth, and complex hospital generics recovered as prior actions against Chinese competition began to help. Management emphasized operating leverage, utilization and mix as margin drivers, but noted that customer decision cycles remain elongated, capex will ramp later in the year, and quarterly delivery can still be uneven. They said it is too early to revise the outlook and may update after the September quarter.
PPLPHARMA Stock Growth Drivers
PPLPHARMA Stock Growth Drivers
10Broad-Based Revenue Growth and Margin Expansion
The company delivered a strong start to FY27, with all three businesses producing mid-to-high teen
CDMO Commercial Momentum and Demand Recovery
The CDMO business showed clear strength, with broad-based growth across India and overseas sites supported
PPLPHARMA Stock Challenges
PPLPHARMA Stock Challenges
3Persistent Chinese Competitive Pressure in Generics
The company continues to face a difficult competitive environment from Chinese players in complex hospital
Elevated Tax Burden with Limited Near-Term Relief
Tax expense was higher year over year because more profit was earned in tax-paying jurisdictions
PPLPHARMA Forecast
PPLPHARMA Forecasts
Price
Revenue
Earnings
PPLPHARMA Share Price Forecast
PPLPHARMA Share Price Forecast
2026
Current
₹208.16
Baseline
Forecast for Sep 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹208.16
Baseline
Forecast for Sep 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
PPLPHARMA Company Revenue Forecast
PPLPHARMA Company Revenue Forecast
2026
Current
₹9.16
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹9.16
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
PPLPHARMA Stock EPS (Earnings Per Share) Forecast
PPLPHARMA Stock EPS (Earnings Per Share) Forecast
2026
Current
₹-2.46
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹-2.46
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
PPLPHARMA
PPLPHARMA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
PPLPHARMA Income Statement
PPLPHARMA Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,590.78 | 1,993.08 | 2,320.12 | 2,233.40 | 2,812.32 | 2,031.42 | 2,124.11 | 2,193.37 | 2,811.40 | 2,378.89 | ||||||||||
Operating & Other expenses | 2,052.95 | 1,746.65 | 1,900.14 | 1,866.48 | 2,193.08 | 1,827.01 | 1,885.03 | 1,985.25 | 2,467.03 | 2,074.72 | ||||||||||
EBITDA | 537.83 | 246.43 | 419.98 | 366.92 | 619.24 | 204.41 | 239.08 | 208.12 | 344.37 | 304.17 | ||||||||||
| Depreciation/Amortization | 196.13 | 184.55 | 192.22 | 196.81 | 242.76 | 197.28 | 202.84 | 212.74 | 218.38 | 223.55 | ||||||||||
| PBIT | 341.70 | 61.88 | 227.76 | 170.11 | 376.48 | 7.13 | 36.24 | -4.62 | 125.99 | 80.62 | ||||||||||
| Interest & Other Items | 114.22 | 106.96 | 107.64 | 103.31 | 103.68 | 86.15 | 82.42 | 89.24 | 82.99 | 88.08 | ||||||||||
| PBT | 227.48 | -45.08 | 120.12 | 66.80 | 272.80 | -79.02 | -46.18 | -93.86 | 43.00 | -7.46 | ||||||||||
| Taxes & Other Items | 126.21 | 43.56 | 97.53 | 63.12 | 119.30 | 2.68 | 53.04 | 42.33 | 51.83 | 61.93 | ||||||||||
| Net Income | 101.27 | -88.64 | 22.59 | 3.68 | 153.50 | -81.70 | -99.22 | -136.19 | -8.83 | -69.39 | ||||||||||
| EPS | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.62 | -0.75 | -1.03 | -0.07 | -0.52 |
PPLPHARMA Company Updates
FY 2027FY 2027
Investor Presentation
Jul 29PDF
PPLPHARMA Stock Peers
PPLPHARMA Past Performance & Peer Comparison
PPLPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Piramal Pharma Ltd (Mumbai) | -84.62 | 3.38 | — |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
PPLPHARMA Stock Price Comparison
Compare PPLPHARMA with any stock or ETFCompare PPLPHARMA with any stock or ETF
PPLPHARMA
PPLPHARMA Holdings
PPLPHARMA Shareholdings
PPLPHARMA Promoter Holdings Trend
PPLPHARMA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
PPLPHARMA Institutional Holdings Trend
PPLPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 17.66%
PPLPHARMA Shareholding Pattern
PPLPHARMA Shareholding Pattern
PPLPHARMA Shareholding History
PPLPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in PPLPHARMA
Mutual Funds Invested in PPLPHARMA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Piramal Pharma Ltd (Mumbai)
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4681% | Percentage of the fund’s portfolio invested in the stock 1.49% | Change in the portfolio weight of the stock over the last 3 months 0.30% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/87 (+4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1930% | Percentage of the fund’s portfolio invested in the stock 2.01% | Change in the portfolio weight of the stock over the last 3 months 0.52% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 60/107 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1866% | Percentage of the fund’s portfolio invested in the stock 0.48% | Change in the portfolio weight of the stock over the last 3 months 0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 77/101 (+3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PPLPHARMA stock
smallcases containing PPLPHARMA stock
Looks like this stock is not in any smallcase yet.
PPLPHARMA Events
PPLPHARMA Events
PPLPHARMA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PPLPHARMA Dividend Trend
No dividend trend available
PPLPHARMA Upcoming Dividends
PPLPHARMA Upcoming Dividends
No upcoming dividends are available
PPLPHARMA Past Dividends
PPLPHARMA Past Dividends
Cash Dividend
Ex DateEx DateJul 16, 2025
Final
Final | Div/Share: ₹0.14
Dividend/Share
₹0.14
Ex DateEx Date
Jul 16, 2025
Cash Dividend
Ex DateEx DateJul 12, 2024
Final
Final | Div/Share: ₹0.11
Dividend/Share
₹0.11
Ex DateEx Date
Jul 12, 2024
PPLPHARMA Stock News & Opinions
PPLPHARMA Stock News & Opinions
Articles & Videos
Spotlight
Spotlight
Piramal Pharma Ltd drops for fifth straight sessionPiramal Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 202.53, down 0.46% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.65% on the day, quoting at 23269.55. The Sensex is at 74411.94, up 0.55%.Piramal Pharma Ltd has eased around 1.07% in last one month.Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has eased around 0.81% in last one month and is currently quoting at 26188.4, down 0.23% on the day. The volume in the stock stood at 20.96 lakh shares today, compared to the daily average of 43.66 lakh shares in last one month.The PE of the stock is 34.97 based on TTM earnings ending June 26.
4 days agoCapital Market - Live
Spotlight
Spotlight
Piramal Pharma Ltd rises for third straight sessionPiramal Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 217.4, up 1.14% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.08% on the day, quoting at 24109.8. The Sensex is at 77095.62, up 0.21%. Piramal Pharma Ltd has gained around 11.1% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has gained around 1.9% in last one month and is currently quoting at 26848.75, up 0.1% on the day. The volume in the stock stood at 40.78 lakh shares today, compared to the daily average of 62.08 lakh shares in last one month.The PE of the stock is 36.92 based on TTM earnings ending June 26.
3 weeks agoCapital Market - Live
Corporate
Corporate
Piramal Pharma’s acquisition of Yapan Bio boosts stake to 74% for roughly Rs 76 croresPiramal Pharma Limited has completed the acquisition of 1,46,400 equity shares of Rs 10 each from existing shareholders of Yapan Bio Private Limited for approximately Rs 76 crores, increasing its stake in the contract development and manufacturing organization from 33.33% to 74.00%, thereby making Yapan a subsidiary of Piramal Pharma.
1 month agoCapital Market - Live
Spotlight
Spotlight
Piramal Pharma Ltd spurts 1.04%, up for five straight sessionsPiramal Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 210.4, up 1.04% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.32% on the day, quoting at 24557.05. The Sensex is at 78532.55, down 0.53%. Piramal Pharma Ltd has added around 25.16% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 4.16% in last one month and is currently quoting at 26564.8, down 0.29% on the day. The volume in the stock stood at 21.45 lakh shares today, compared to the daily average of 77.11 lakh shares in last one month.The PE of the stock is 35.79 based on TTM earnings ending June 26.
1 month agoCapital Market - Live
Spotlight
Spotlight
Piramal Pharma Ltd gains for third straight sessionPiramal Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 206.49, up 1.97% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 24523.85. The Sensex is at 78409.43, down 0.02%. Piramal Pharma Ltd has gained around 16.08% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has gained around 2.37% in last one month and is currently quoting at 26597.5, down 0.44% on the day. The volume in the stock stood at 57.02 lakh shares today, compared to the daily average of 76.51 lakh shares in last one month.The PE of the stock is 34.78 based on TTM earnings ending June 26.
1 month agoCapital Market - Live
Earnings
Earnings
Piramal Pharma reports consolidated net loss of Rs 69.39 crore in the June 2026 quarterNet Loss of Piramal Pharma reported to Rs 69.39 crore in the quarter ended June 2026 as against net loss of Rs 81.70 crore during the previous quarter ended June 2025. Sales rose 17.39% to Rs 2269.92 crore in the quarter ended June 2026 as against Rs 1933.71 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales2269.921933.71 17 OPM %8.605.52 - PBDT216.0997.52 122 PBT-7.46-99.76 93 NP-69.39-81.70 15 Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Spotlight
Piramal Pharma Ltd soars 0.83%, gains for fifth straight sessionPiramal Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 195.03, up 0.83% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.98% on the day, quoting at 24220.8. The Sensex is at 77561.47, up 1.04%. Piramal Pharma Ltd has gained around 16.03% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has gained around 3.99% in last one month and is currently quoting at 25998.85, up 1.3% on the day. The volume in the stock stood at 88.78 lakh shares today, compared to the daily average of 76.36 lakh shares in last one month.The PE of the stock is 33.52 based on TTM earnings ending March 26.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Piramal Pharma announces board meeting datePiramal Pharma will hold a meeting of the Board of Directors of the Company on 29 July 2026.
2 months agoCapital Market - Live
Corporate
Corporate
Piramal Pharma receives Establishment Inspection Report for Sellersville unitsPiramal Pharma announced that USFDA has issued an Establishment Inspection Report (EIR) for the company's manufacturing facility located at Sellersville (USA) and the inspection has now been successfully closed by USFDA.
2 months agoCapital Market - Live
Corporate
Corporate
Piramal Pharma to conduct AGMPiramal Pharma announced that the Annual General Meeting(AGM) of the company will be held on 30 July 2026.
2 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 6.96%, vs industry avg of 11.76%
Over the last 5 years, market share decreased from 2.25% to 1.79%